Veradermics, Incorporated (MANE)Healthcare | Biotechnology | New Haven, United States | NYSE
108.82 USD
-6.25
(-5.431%) ⇩
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 108.82 |
Hot Take ↕ | Oct. 10, 2026, 9:21 a.m. EDT
Veradermics presents a compelling risk-reward profile driven by a fortress balance sheet and recent positive clinical trial data, yet it remains a speculative biotech play without earnings. The stock trades significantly above its 50- and 200-day averages, confirming strong momentum, though the statistical forecast model offers no directional clarity. While analysts maintain a strong buy stance with a target price well above current levels, the absence of profitability and the heavy reliance on future pipeline success necessitates caution. The options market reflects this tension with elevated near-term volatility and mixed positioning, suggesting traders are preparing for a binary outcome rather than a linear grind. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.077987 |
| AutoETS | 0.087202 |
| AutoTheta | 0.203352 |
| AutoARIMA | 0.310338 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 2.82 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.356 |
| Excess Kurtosis | -1.04 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.053 |
| Market Cap | 4,546,514,432 |
| Forward P/E | -40.39 |
| Website | https://www.veradermics.com |
As of Oct. 10, 2026, 9:21 a.m. EDT: Near-term implied volatility is significantly elevated compared to longer-dated contracts, indicating heightened uncertainty surrounding the October expiration. Call open interest clusters at the 140 strike, suggesting bullish positioning for a move above current levels, while put volume concentrates at the 80 strike, reflecting a hedge against a deeper correction. The term structure inversion points to event-driven speculation rather than steady directional conviction.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.0482118 |
| Address1 | 470 James Street |
| Address2 | Suite 2 |
| All Time High | 136.72 |
| All Time Low | 32.0 |
| Ask | 130.0 |
| Ask Size | 300 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 1,013,990 |
| Average Daily Volume3 Month | 776,677 |
| Average Volume | 776,677 |
| Average Volume10Days | 1,013,990 |
| Bid | 100.0 |
| Bid Size | 100 |
| Book Value | 19.474 |
| City | New Haven |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 108.82 |
| Current Ratio | 70.527 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 114.25 |
| Day Low | 106.7 |
| Debt To Equity | 0.053 |
| Display Name | Veradermics |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,786,451,400 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 3,727,048,448 |
| Eps Current Year | -2.88748 |
| Eps Forward | -2.69413 |
| Eps Trailing Twelve Months | -4.01 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 20 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 109.2598 |
| Fifty Day Average Change | -0.43980408 |
| Fifty Day Average Change Percent | -0.0040253056 |
| Fifty Two Week Change Percent | 204.82118 |
| Fifty Two Week High | 136.72 |
| Fifty Two Week High Change | -27.900002 |
| Fifty Two Week High Change Percent | -0.20406671 |
| Fifty Two Week Low | 32.0 |
| Fifty Two Week Low Change | 76.82 |
| Fifty Two Week Low Change Percent | 2.400625 |
| Fifty Two Week Range | 32.0 - 136.72 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,770,215,400,000 |
| Float Shares | 32,290,614 |
| Forward Eps | -2.69413 |
| Forward P E | -40.391518 |
| Full Exchange Name | NYSE |
| Full Time Employees | 37 |
| Fullday Change | -6.25 |
| Fullday Change Percent | -5.4314766 |
| Fullday Price | 108.82 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02487 |
| Held Percent Institutions | 0.98484004 |
| Implied Shares Outstanding | 41,780,136 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut. |
| Market | us_market |
| Market Cap | 4,546,514,432 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_684321879 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -104,290,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,935,905,267 |
| Number Of Analyst Opinions | 6 |
| Open | 114.19 |
| Operating Cashflow | -78,300,000 |
| Operating Margins | 0.0 |
| Phone | 228 372 3376 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 108.82 |
| Post Market Time | 1,792,180,818 |
| Previous Close | 115.07 |
| Price Eps Current Year | -37.68684 |
| Price Hint | 2 |
| Price To Book | 5.587963 |
| Profit Margins | 0.0 |
| Quick Ratio | 70.248 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.14286 |
| Region | US |
| Regular Market Change | -6.25 |
| Regular Market Change Percent | -5.43148 |
| Regular Market Day High | 114.25 |
| Regular Market Day Low | 106.7 |
| Regular Market Day Range | 106.7 - 114.25 |
| Regular Market Open | 114.19 |
| Regular Market Previous Close | 115.07 |
| Regular Market Price | 108.82 |
| Regular Market Time | 1,792,180,802 |
| Regular Market Volume | 672,880 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 41,780,136 |
| Shares Percent Shares Out | 0.1016 |
| Shares Short | 4,244,476 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 4,025,420 |
| Short Name | Veradermics, Incorporated |
| Short Percent Of Float | 0.156 |
| Short Ratio | 5.78 |
| Source Interval | 15 |
| State | CT |
| Symbol | MANE |
| Target High Price | 182.0 |
| Target Low Price | 135.0 |
| Target Mean Price | 163.5 |
| Target Median Price | 167.0 |
| Total Cash | 819,894,016 |
| Total Cash Per Share | 19.624 |
| Total Debt | 428,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.01 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 91.310905 |
| Two Hundred Day Average Change | 17.509094 |
| Two Hundred Day Average Change Percent | 0.1917525 |
| Type Disp | Equity |
| Volume | 672,880 |
| Website | https://www.veradermics.com |
| Zip | 6,513 |